Authors
Latest:
How the SECURE Act affects inherited IRAsLegislation sets 10-year withdrawal window for nonspouse beneficiaries.
Latest:
The evolving role of microRNAs in testicular cancer management"This brief review captures the evolving role of miRNAs, focusing on their clinical relevance and implications as well as future directions for more effective targeted therapeutic interventions," write the authors.
Latest:
CLEAR trial analyses reaffirm benefit of lenvatinib/pembrolizumab in aRCC"The updated results from CLEAR trial confirming that the amount of tumor shrinkage correlates with prognosis through overall survival, PFS, as well as through IMDC prognostic scoring should add further weight to lenvatinib and pembrolizumab being a go-to standard of care in this setting," says Thomas E. Hutson, DO, PharmD.
Latest:
2024 Urology Times pipeline reportCatch up on all the notable drug and device approvals in urology over the past year.
Latest:
Dr. Schwen on focal therapies for prostate cancerZeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Latest:
Future Directions for Imaging and Biopsy in Prostate CancerThe panel offers key takeaways on the evolving landscape for imaging and biopsy in prostate cancer, highlighting the role for fusion-guided biopsy in the diagnosis and management of prostate cancer.
Latest:
Margaret Knoedler, MD, on Ho:YAG vs thulium fiber laser for ureteroscopy"The decision for which laser to use in your institution should be left up to the urologist and the hospital system," says Margaret A. Knoedler, MD.
Latest:
Artificial intelligence is the new ghost author in urological research“Although the future of AI within science is uncertain, disclosure of the use of AI is an excellent first step to balance academic integrity with disruptive innovation,” the authors write.
Latest:
Nivolumab/Cabozantinib combo continues to show HRQOL benefit in renal cell carcinomaLong-term follow-up from the CheckMate 9ER trial continued to show that first-line treatment with nivolumab plus cabozantinib was associated with a health-related quality-of-life benefit over treatment with sunitinib in patients with advanced renal cell carcinoma .
Latest:
Thomas Mueller, MD, on the removal of residual stone fragments“The 1 main assumption that we've been very wrong on although we've had the data for a long period of time, [is that] although we assume that the stone fragments are small enough to pass, oftentimes they don't,” says Thomas Mueller, MD.
Latest:
Suffering from Bladder or Pelvic Floor Issues? Here’s How a Urogynecologist Can HelpUrogynecologists focus on female pelvic medicine and reconstructive surgery, handling issues related to the pelvic floor and bladder.
Latest:
Laura Bukavina, MD, on trial of radiation with concurrent sacituzumab govitecan in MIBCThe trial is assessing the safety and tolerability of adaptive radiation therapy with concurrent sacituzumab govitecan in patients with MIBC.
Latest:
Key Trials on PARP Inhibitor Combinations in Metastatic Prostate Cancer: Efficacy and Future ConsiderationsPanelists discuss how the increased use of androgen receptor–targeted therapy in clinical practice may impact the effectiveness of PARP inhibitor combinations like talazoparib in the TALAPRO-2 study, while also addressing safety concerns, potential differences in trial populations, and the need for future studies to optimize treatment approaches for various metastatic prostate cancer patient subgroups.
Latest:
Michelle Sheng, MD, on strategies to improve female representation in urology“I think promoting women in leadership positions, promoting mentorship for women applicants and women already in this field, and working on policy changes are the top 3,” says Michelle S. Sheng, MD.
Latest:
Novel FGFR2/3 inhibitor shows promise in solid tumors, including bladder cancerThe novel agent ABSK061 approached a response rate of 40% in patients with advanced solid tumors harboring FGFR2/3 alterations.
Latest:
Final Thoughts and Clinical Trials in NMIBCExperts share their concluding thoughts on the recent progress and future outlook for the treatment of non–muscle-invasive bladder cancer (NMIBC).
Latest:
Jim Hu, MD, on urinary continence recovery across RARP techniquesJim C. Hu, MD, MPH, shares in-depth findings comparing urinary continence recovery across 3 RARP approaches.
Latest:
Joy Maulik, CRNP, on the importance of genetic testing in prostate cancer“I truly think genetic testing should be incorporated as a part of daily care in prostate cancer,” says Joy Maulik, CRNP.
Latest:
Real-time IRP monitoring may redefine safety and scope of flexible ureteroscopyProfessor Andreas Skolarikos shares his experience with the LithoVue Elite System.
Latest:
Scott Tagawa, MD, highlights phase 3 trial of 177Lu-TLX591 in mCRPCProstACT GLOBAL is assessing the safety and efficacy of 177Lu-TLX591 plus SOC vs SOC alone in patients with mCRPC.
Latest:
Is your practice equipped to battle ransomware attacks?3 steps to protect your practice from ransomware.
Latest:
Frontline masitinib combo delays progression in mCRPC with low metastatic involvementAdding the investigational agent masitinib to standard frontline docetaxel significantly reduced the risk of disease progression or death in men with metastatic castration-resistant prostate cancer and baseline alkaline phosphatase levels (ALP) of 250 IU/mL or less.
Latest:
Going “retro”: A perspective on robotic retroperitoneal renal surgeryImprovements in technology have renewed interest in the technique.
Latest:
Management of hormone-naïve oligometastatic prostate cancerGrowing evidence supports the existence of an intermediate metastatic disease state.
Latest:
The Future of Prostate Cancer ImagingProstate cancer experts highlight some closing thoughts and exciting research in progress on prostate cancer imaging.
Latest:
Key Takeaways on Evolving Bladder Cancer Treatment LandscapeThe expert panel concludes its discussion by providing key takeaways on the evolving bladder cancer treatment landscape following ESMO 2023.
Latest:
Juan J. Andino, MD, on how urologists can get involved in health advocacy“There's state advocacy work groups and other public policy work groups where folks can remain involved and keep pushing to improve the delivery of health care,” says Juan J. Andino, MD, MBA.
Latest:
Expert shares best practices to improve patient collectionsImproving your patient payment process in 2023 is important to maintain a positive relationship with your patients and with your practice’s bottom line.
Latest:
Tools urologists need to thrive in a value-based worldPractices must embark on a journey that goes beyond new technology.
